A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses

MLA

James Tristan Gordy, et al. “A SARS-CoV-2 RBD Vaccine Fused to the Chemokine MIP-3α Elicits Sustained Murine Antibody Responses over 12 Months and Enhanced Lung T-Cell Responses.” Frontiers in Immunology, vol. 15, Feb. 2024. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1292059.

APA

James Tristan Gordy, Yinan Hui, Courtney Schill, Tianyin Wang, Fengyixin Chen, Kaitlyn Fessler, Jacob Meza, Yangchen Li, Alannah D. Taylor, Rowan E. Bates, Petros C. Karakousis, Andrew Pekosz, Jaiprasath Sachithanandham, Maggie Li, Styliani Karanika, & Richard B. Markham. (2024). A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1292059

Chicago

James Tristan Gordy, Yinan Hui, Courtney Schill, Tianyin Wang, Fengyixin Chen, Kaitlyn Fessler, Jacob Meza, et al. 2024. “A SARS-CoV-2 RBD Vaccine Fused to the Chemokine MIP-3α Elicits Sustained Murine Antibody Responses over 12 Months and Enhanced Lung T-Cell Responses.” Frontiers in Immunology 15 (February). doi:10.3389/fimmu.2024.1292059.